Co-led $65M Series A for Helicore Biopharma, a GIP antagonist developer focused on obesity therapeutics.
Helicore Bio is developing long-acting therapies in obesity and cardiometabolic disease using our proprietary antibody-peptide conjugate platform
Helicore Bio is developing long-acting therapies in obesity and cardiometabolic disease using our proprietary antibody-peptide conjugate platform. We have developed proprietary libraries of GLP-1R agonist and amylin receptor agonist therapeutic peptides, optimized for relevant bias, selectivity, and potency characteristics.